Biomagnetics Diagnostics Schedules Investor Update Conference Call

SAN FRANCISCO--(BUSINESS WIRE)-- Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced it will hold a conference call on Wednesday, January 12, 2011 at 4:15 PM (EST) to provide investors with an update on corporate activities.

"We look forward to updating our investors," commented Clayton Hardman, CEO of Biomagnetics. "On the conference call we plan to discuss the status of our Chinese acquisitions and our 2011 plans for the integrated optical biosensor product line, which we are developing in conjunction with Los Alamos National Laboratory. We are especially excited about the development of the tuberculosis and cholera test assays for the biosensor product line as we believe these hold the promise to revolutionize diagnostics for these diseases. Please join us next week as we discuss these and other issues and provide time for our investors to ask any questions of the management team."

Any interested participants may dial into the Biomagnetics Diagnostics Corp. conference call using the toll free dial-in number (US & Canada) (866) 576-7975 or the international dial-in number of (760) 569-7000. The Participant access code is 622190.

About Biomagnetics Diagnostics Corp.

Biomagnetics Diagnostics Corporation is an advanced medical device and biotechnology company. The Company is currently developing a waveguide-based advanced integrated optical biosensor through its cooperative research and development agreement with Los Alamos National Security, LLC, which will initially be used for cholera, tuberculosis and malaria diagnosis. More information on Biomagnetics Diagnostics Corp. can be seen at www.biomagneticsbmgp.com.



CONTACT:

Biomagnetics Diagnostics Corp.
Paul Hardman, 916-987-7078

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Infectious Diseases  Medical Devices  Research  Science

MEDIA:

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.